4.7 Article

Study on the potential nephrotoxicity and mutagenicity of aristolochic acid IVa and its mechanism

期刊

BIOMEDICINE & PHARMACOTHERAPY
卷 142, 期 -, 页码 -

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.112081

关键词

Aristolochic acid IVa; Nephrotoxicity; Low mutagenicity; Low carcinogenicity

资金

  1. National Natural Science Foundation of China [81974534]
  2. National Science and Technology Major Project [2015ZX09501004, 2018ZX09101002-003]
  3. China Academy of Chinese Medical Sciences [CI2021A04801, CI2021A04806]
  4. Fundamental Research Funds for the Central Public Welfare Research Institutes [ZZ13-035-10, ZZ10025, ZZ13-YQ-055, ZZ12-001, ZXKT19014, ZXKT20022]

向作者/读者索取更多资源

The study found that compared to aristolochic acid I, aristolochic acid IVa has lower effects on nephrotoxicity, mutations, and tumorigenesis in mice, showing no obvious toxicity at certain doses and a lower mutagenicity and carcinogenic risk. Exposure to AAIVa may induce mild renal lesions but does not lead to severe damage or death like AAI.
Previous reports demonstrated that aristolochic acids (AAs) exposure-induced nephrotoxicity, mutations, and tumorigenesis are mainly due to aristolochic acid I (AAI). Notably, the chemical structure of aristolochic acid IVa (AAIVa), which exists at higher levels in many Aristolochiaceae herbs, is extremely similar to AAI. In lack of toxicological data, it is unknown whether AAIVa exposure leads to aristolochic acid nephropathy (AAN), mutations, and tumorigenesis as of AAI. To answer these questions, mice were administered AAIVa by single or repeated long-term gavage, while AAI was used as a positive control. We found that single gavage of 40 mg/kg of AAIVa exhibited no obvious toxicity. Also, there were no tumors or death in mice administrated with 1 and 10 mg/kg of AAIVa for 6 months followed by a 12-month recovery time. There were no noteworthy alterations in gene mutation frequency in the kidney, liver, and stomach between the AAIVa and control mice. Fascinatingly, AA-associated mutational signatures, adenine-to-thymine (A>T) transversions, were absent in AAIVa-treated mice. Nonetheless, 10 mg/kg of AAIVa triggered lymphocytic infiltration and slight fibrous hyperplasia in the kidney at the 6th month; however, these were alleviated at the 12th and 18th months. On the contrary, AAI (positive control) caused severe diffuse fibrosis, tubular atrophy, necrosis, tumors in the forestomach and kidney, and death after the 6th month. It seems that long-term AAIVa exposure induced mild renal lesions could be due to the activation of the canonical or noncanonical transforming growth factor-beta (TGF beta) pathway. Overall, these findings suggest that the mutagenicity and carcinogenic risk of AAIVa are very low.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据